A widely seen and much-celebrated chart maintained by the National Institutes of Health shows how the fall in the cost of sequencing has outstripped the steady decline of Moore's law in recent years. The chart is a visual representation of the race toward the $1,000 genome, but now the industry is feeling the flip side of the graph: It can no longer rely on Moore's law to meet its storage needs.
Genomics England is to work with LabKey Software to develop a data-management platform that meets the needs of the 100,000 Genomes Project. The deal puts the open-source LabKey Server platform at the center of the infrastructure the massive sequencing project will use to integrate and share data.
The University of California, San Francisco (UCSF) has snagged $9.75 million to build a platform for the remote collection of research data. UCSF will use the cash to build out its mobile data gathering toolkit, giving it the capabilities to support large-scale, geographically-dispersed research programs.
Bayer has set up a system to manage its omics data analysis workflow. The system is the result of Bayer's collaboration with Genedata, which has provided its data management and analysis software to a platform that also draws on the capabilities of the open-source iRODS.
J. Craig Venter's Human Longevity Inc. has struck a deal to provide exome sequencing services to the customers of a South Africa-based insurance firm. HLI is charging a meager $250 per exome, but in addition to the cash will get one of the other things it wants: data.
GlaxoSmithKline has hitched its automation plans to Siemens. The deal makes Siemens the preferred automation supplier for production and R&D sites at GSK, positioning the conglomerate to shape how its partner incorporates advances in data integration into its operations.
Labfolder has pulled in more than $1 million to finance development of its electronic lab notebook (ELN) system. The startup will use the cash to advance its vision of creating a system to connect researchers and the networks of equipment, software and data that support their work.
Google is keeping up the pace of its push into diabetes. Having got the ball rolling by allying with Novartis in 2014, Google has now added Sanofi to its burgeoning list of diabetes collaborators.
The FDA has come good on its promise to make its stash of medical device data available publicly.
Biogen is working with Columbia University Medical Center to build a database of genes and clinical traits from 1,500 people with amyotrophic lateral sclerosis (ALS). The project, which is partly funded by cash raised in the Ice Bucket Challenge, is intended to help Biogen understand how genes contribute to different forms of ALS.